References

[1] Ahmed, Z.Z., Khan, F.N. and Shaikh, D.A. (2018). Reverse engineering and formulation by QBD of olopatadine hydrochloride ophthalmic solution. Journal of Pharmaceutical Investigation, 48(3), pp. 279-293.

[2] Bansal, A. and Koradia, V. (2005). The role of reverse engineering in the development of generic formulations.

[3] Berkowitz, S.A., Engen, J.R., Mazzeo, J.R. and Jones, G.B. (2012). Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nature Reviews Drug Discovery, 11(7), pp.527-540.

[4] Paliwal, R., Mamgain, A., Kenwat, R. and Paliwal, S.R. (2021). Reverse Engineering in Pharmaceutical Product Development. In Micro-and Nanotechnologies-Based Product Development (pp. 235-242). CRC Press.

[5] Chen, K., Park, J., Li, F., Patil, S.M. and Keire, D.A. (2018). Chemometric methods to quantify 1D and 2D NMR spectral differences among similar protein therapeutics. AAPS PharmSciTech, 19(3), pp.1011-1019.

[6] Clément, Y., Gaubert, A., Bonhommé, A., Marote, P., Mungroo, A., Paillard, M., Lantéri, P. and Morell, C. (2019). Raman spectroscopy combined with advanced chemometric methods: A new approach for detergent deformulation. Talanta, 195, pp.441-446.

[7] Cotte, J.F., Sonnery, S., Martial, F., Dubayle, J., Dalençon, F., Haensler, J. and Adam, O. (2012). Characterization of surfactants in an oil-in-water emulsion-based vaccine adjuvant using MS and HPLC–MS: Structural analysis and quantification. International journal of pharmaceutics, 436(1-2), pp.233-239.

[8] Duraipandi, S. and Selvakumar, V. (2020). Reinventing nano drug delivery systems for hydrophilic active ingredients in Ayurvedic lipid based formulations containing poly herbal decoction. Journal of Ayurveda and integrative medicine, 11(3), pp.224-227.

[9] Duraipandi, S., Selvakumar, V. and Er, N.Y. (2015). Reverse engineering of Ayurvedic lipid based formulation, ghrita by combined column chromatography, normal and reverse phase HPTLC analysis. BMC complementary and alternative medicine, 15(1), pp.1-6.

[10] Gohel, M.C., Sarvaiya, K.G., Shah, A.R. and Brahmbhatt, B.K. (2009). Mathematical approach for the assessment of similarity factor using a new scheme for calculating weight. Indian Journal of Pharmaceutical Sciences, 71(2), p.142.

[11] Gokhale, M.Y. and Mantri, R.V. (2017). API Solid-Form Screening and Selection. In Developing Solid Oral Dosage Forms (pp. 85-112). Academic Press.

[12] Koradia, V.S., Chawla, G. and Bansal, A.K. (2005). Comprehensive characterisation of the innovator product: targeting bioequivalent generics. Journal of Generic Medicines, 2(4), pp.335-346.

[13] Law, D. and Zhou, D. (2017). Solid-state characterization and techniques. In Developing Solid Oral Dosage Forms (pp. 59-84). Academic Press.

[14] Matsui, K., Takeuchi, S., Haruna, Y., Yamane, M., Shimizu, T., Hatsuma, Y., Shimono, N., Sunada, M., Hayakawa, M., Nishida, T. and Ito, S. (2020). Transverse comparison of mannitol content in marketed drug products: Implication for no-effect dose of sugar alcohols on oral drug absorption. Journal of Drug Delivery Science and Technology, 57, p.101728.

[15] Nie, H., Mo, H. and Byrn, S.R. (2018). Investigating the physicochemical stability of highly purified darunavir ethanolate extracted from prezista® tablets. AAPS PharmSciTech, 19(5), pp.2407-2417.

[16] Zahid, Z., Furquan, N., Sarfaraz, K., Moizul, H., Obaid, S. and Raheel, K. (2016). Reverse engineering and development of generic Orlistat formulation. JIPBS, 3(4), pp.17-25.

[17] Munjal, Bhushan et al. (2015). “Role of Innovator Product Characterization in Generic Product Development.”